Friday, March 1, 2013

CardioKinetix Scores $48M For Heart Failure Treatment

Menlo Park-based CardioKinetix said Thursday that it has raised $48M in a Series E financing, for its catheter-based heart failure therapies. The new funding round came from Panorama Capital, along with prior investors U.S. Venture Partners, JPMorgan Partners, New Leaf Venture Partners, SV Life Sciences, H&Q Healthcare Investors, and H&Q Life Sciences Investors. The most recent funding came in the form of a $23M, second tranche of its Series E. The firm said it will use the financing to further advance its programs. Maria Sainz is President and CEO of CardioKinetix. More information »